lundi 11 février 2019

Onco Actu du 11 février 2019


1. BIOLOGIE



New insight into cell receptors opens the way for tailored cancer drugs [Karolinska Institutet]











1.4 BIOLOGIE - TECHNOS



New patent win for University of California upends CRISPR legal battle [Science]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Juul instigated a “nicotine arms race”, researchers say [Stanford Medicine]











FDA chief accuses Juul, Altria of reneging on promise to combat 'epidemic' teen vaping use [CNBC]











Nick Hopkinson: The prominence of e-cigarettes is a symptom of decades of failure to address smoking properly [BMJ]










4.10 DÉP., DIAG. & PRONO. - POUMON



NHS to roll out mobile lung cancer scanning across England [Cancer Research UK]











After Lung Cancer Screening, Follow-Up Procedures May Be Riskier than Thought [NCI]










NHS to screen for lung cancer in trucks in supermarket car parks [The Guardian]











Lung cancer needn’t be a killer. NHS mobile chest scans will save lives [The Guardian]










4.12 BIOPSIES LIQUIDES



Illumina Details NCI Effort to Validate NGS Oncology Panel for Liquid Biopsies [Genome Web]











4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



Henry Kitchener: Primary cervical screening with human papillomavirus testing [BMJ]











4.9 DÉP., DIAG. & PRONO. - SEIN



Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35–39 at Increased Familial Risk of Breast Cancer [EClinicalMedicine]











Annual screening detects breast cancers earlier for women aged 35-39 with a family history [University of Manchester]










Breast cancer: Scan younger women at risk, charity says [BBC News]











5. TRAITEMENTS



Challenges to curing primary brain tumours [Nature Reviews Clinical Oncology]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Merck]











Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer [EndPoints]











Rutgers scientists form immuno-oncology biotech to develop pipeline of TAM inhibitors [EndPoints]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Canaan leaps into UK biotech by co-leading $14M Series A for immuno-oncology upstart Grey Wolf [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma [Seattle Genetics]











5.3 TRAITEMENTS - FDA, EMA, NICE...



EMA launches checklist to facilitate validation for initial marketing authorisation applications [EMA]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015 [European Journal of Cancer]










European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [BMS]











5.4 TRAITEMENTS - ECONOMIE



Does The NIH Deserve A Piece Of Biopharma's Profits? [Forbes]











Why Is Medicine So Expensive? [New York Review of Books]











6.12 ETHIQUE



Doctor payments drove scripts for cancer drugs from Pfizer, Novartis and more: study [Fierce Pharma]











Vinay Prasad: A wake-up call for the medical profession [BMJ]











6.7 DMP, BIG DATA & APPLIS



Making the NHS ready for the digital revolution [NHS]










6.7.1 IA/BIOINFORMATIQUE



Trump’s Plan to Keep America First in AI [Wired]











Trump to launch artificial intelligence initiative, but many details lacking [Science]











ACD Working Group on Artificial Intelligence [NIH]